Regional gene therapy to enhance bone repair

Gene therapy presents a novel approach to the treatment of challenging bone loss problems. Recombinant, osteogenic growth factors are now available to enhance bone repair, particularly in those applications related to the treatment of fracture nonunions and the enhancement of fusion of the spine. However, there is concern that a single dose of an exogenous protein will not induce an adequate osteogenic signal in many patients, particularly in those cases where there is compromise of host bone and the surrounding soft tissue. Transfer of genes encoding osteogenic proteins has the potential to overcome the delivery problems associated with the use of the proteins themselves. Bone healing is an attractive application for gene therapy, because long-term protein production is not necessary for many bone repair problems. Therefore, the development of gene therapy strategies to treat bone repair problems promises to be easier than the application of gene therapy to treat chronic diseases. The purpose of this review is to highlight the advantages, disadvantages and clinical potential of various gene therapy strategies to enhance bone repair.

[1]  K. Kraus,et al.  Mesenchymal stem cells in osteobiology and applied bone regeneration. , 1998, Clinical orthopaedics and related research.

[2]  R. Samulski,et al.  AAV vectors: is clinical success on the horizon? , 2000, Gene Therapy.

[3]  B. Summers,et al.  DONOR SITE PAIN FROM THE ILIUM , 1989 .

[4]  T. Tursz,et al.  Immune Response to Recombinant Adenovirus in Humans: Capsid Components from Viral Input Are Targets for Vector-Specific Cytotoxic T Lymphocytes , 2000, Journal of Virology.

[5]  J. Engh,et al.  In vivo endochondral bone formation using a bone morphogenetic protein 2 adenoviral vector. , 1999, Human gene therapy.

[6]  J. Engh,et al.  Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. , 2000, Journal of neurosurgery.

[7]  R. Lindsay,et al.  Anabolic actions of parathyroid hormone on bone. , 1993, Endocrine reviews.

[8]  F. Graham,et al.  Intramarrow cytokine gene transfer by adenoviral vectors in dogs. , 1997, Human gene therapy.

[9]  Christian Lattermann,et al.  A gene therapy approach to accelerating bone healing Evaluation of gene expression in a New Zealand white rabbit model , 1999, Knee Surgery, Sports Traumatology, Arthroscopy.

[10]  Banwart Jc,et al.  Iliac crest bone graft harvest donor site morbidity. A statistical evaluation. , 1995 .

[11]  H. Redmond,et al.  Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Longaker,et al.  Adenovirus‐Mediated Gene Therapy of Osteoblasts In Vitro and In Vivo , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  A Daluiski,et al.  The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. , 1999, The Journal of bone and joint surgery. American volume.

[14]  G. Ciliberto,et al.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H N Herkowitz,et al.  Pseudarthrosis of the spine. , 1992, Clinical orthopaedics and related research.

[16]  N. Hackett,et al.  Variability of Human Systemic Humoral Immune Responses to Adenovirus Gene Transfer Vectors Administered to Different Organs , 1999, Journal of Virology.

[17]  C. Kao,et al.  Osteogenesis in rats induced by a novel recombinant helper‐dependent bone morphogenetic protein‐9 (BMP‐9) adenovirus , 2003, The journal of gene medicine.

[18]  S. Miyatake,et al.  Osteoinduction by bone morphogenetic protein-2 via adenoviral vector under transient immunosuppression. , 2000, Biochemical and biophysical research communications.

[19]  M. Lusky,et al.  Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. , 1997, Immunology letters.

[20]  S. Santavirta,et al.  Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures: A Prospective, Controlled, Randomized Study of Four Hundred and Fifty Patients , 2002, The Journal of bone and joint surgery. American volume.

[21]  B. Summers,et al.  Donor site pain from the ilium. A complication of lumbar spine fusion. , 1989, The Journal of bone and joint surgery. British volume.

[22]  S. Boden,et al.  Use of Recombinant Human Bone Morphogenetic Protein-2 to Achieve Posterolateral Lumbar Spine Fusion in Humans: A Prospective, Randomized Clinical Pilot Trial 2002 Volvo Award in Clinical Studies , 2002, Spine.

[23]  S. Miyatake,et al.  In Vitro and in Vivo Studies of a Bone Morphogenetic Protein-2 Expressing Adenoviral Vector , 2001, The Journal of bone and joint surgery. American volume.

[24]  A. Reddi.  Initiation of fracture repair by bone morphogenetic proteins. , 1998, Clinical orthopaedics and related research.

[25]  P. Robbins,et al.  Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. , 1999, Bone.

[26]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Evans,et al.  Gene transfer approaches to the healing of bone and cartilage. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  R Krauspe,et al.  Potential role of direct adenoviral gene transfer in enhancing fracture repair. , 2000, Clinical orthopaedics and related research.

[29]  L. Titus,et al.  1998 Volvo Award Winner in Basic Science Studies: Lumbar Spine Fusion by Local Gene Therapy With a cDNA Encoding a Novel Osteoinductive Protein (LMP‐1) , 1998, Spine.

[30]  S. Goldstein,et al.  Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Marc A. Asher,et al.  Iliac Crest Bone Graft Harvest Donor Site Morbidity: A Statistical Evaluation , 1995, Spine.

[32]  H. Chambers,et al.  Complications of iliac crest bone graft harvesting. , 1996, Clinical orthopaedics and related research.

[33]  W. Hayes,et al.  Bone regeneration by implantation of purified, culture‐expanded human mesenchymal stem cells , 1998, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[34]  D. Kallmes,et al.  Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy. , 1999, Journal of neurosurgery.

[35]  Jeffrey Bonadio,et al.  Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration , 1999, Nature Medicine.

[36]  T. Kurata,et al.  CELLULAR AND HUMORAL IMMUNE RESPONSES IN MICE , 1973 .

[37]  P. Campbell,et al.  Effect of Regional Gene Therapy with Bone Morphogenetic Protein-2-Producing Bone Marrow Cells on Spinal Fusion in Rats , 2003, The Journal of bone and joint surgery. American volume.

[38]  Freddie H. Fu,et al.  Enhancement of Tendon-Bone Integration of Anterior Cruciate Ligament Grafts with Bone Morphogenetic Protein-2 Gene Transfer: A Histological and Biomechanical Study , 2002, The Journal of bone and joint surgery. American volume.

[39]  P. Robbins,et al.  Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene , 2000, Gene Therapy.

[40]  M. Kabo,et al.  GENETICALLY MODIFIED STEM CELLS DERIVED FROM HUMAN ADIPOSE TISSUE CAN HEAL CRITICALLY SIZED FEMORAL DEFECTS IN ATHYMIC RATS , 2001 .

[41]  W. Hutton,et al.  Adenoviral Delivery of LIM Mineralization Protein-1 Induces New-Bone Formation in Vitro and in Vivo , 2001, The Journal of bone and joint surgery. American volume.

[42]  M. Longaker,et al.  Expression of Adenovirally Delivered Gene Products in Healing Osseous Tissues , 2000, Annals of plastic surgery.

[43]  S. Goldstein,et al.  In vivo nonviral delivery factors to enhance bone repair. , 2000, Clinical orthopaedics and related research.

[44]  D. Oakes,et al.  Osteoinductive applications of regional gene therapy: ex vivo gene transfer. , 2000, Clinical orthopaedics and related research.

[45]  R. Rutherford,et al.  Bone morphogenetic protein-transduced human fibroblasts convert to osteoblasts and form bone in vivo. , 2002, Tissue engineering.

[46]  H. Chiou,et al.  Obstacles and advances in non-viral gene delivery. , 2000, Current opinion in molecular therapeutics.

[47]  A. Reddi.  Bone and cartilage differentiation. , 1994, Current opinion in genetics & development.

[48]  Johnny Huard,et al.  Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. , 2002, The Journal of clinical investigation.

[49]  H. Lorenz,et al.  Multilineage cells from human adipose tissue: implications for cell-based therapies. , 2001, Tissue engineering.

[50]  S. Bruder,et al.  Monoclonal antibodies reactive with human osteogenic cell surface antigens. , 1997, Bone.

[51]  J. Engh,et al.  The Use of Bone Morphogenetic Protein Gene Therapy in Craniofacial Bone Repair , 2000, The Journal of craniofacial surgery.

[52]  G. Zych,et al.  Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in the Treatment of Tibial Nonunions: A Prospective, Randomized Clinical Trial Comparing rhOP-1 with Fresh Bone Autograft* , 2001, The Journal of bone and joint surgery. American volume.

[53]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.